



PLCOSKIN

Plcoskin has developed a scaffold that removes the need for cadaver-sourced material used in breast reconstruction surgery, making procedures safer and cheaper.

GIVING WOMEN HOPE

The most common cancer for women is breast cancer, which makes up almost a quarter of all cancers globally. For women who require mastectomies, breast reconstruction surgery is a preferred option, but it's expensive and not typically covered by health insurers. In fact, 80% of Korean women cannot afford this surgery, that leads to permanent disfigurement and high rates of depression.

Breast reconstruction relies on skin scaffolds to cover the silicone breast implants. Existing methods for creating these scaffolds rely on skin from chemically treated human cadavers, which can cause infection and lead to dangerous side-effects in 10% of all patients.



PLOSKIN: A SAFER, BIODEGRADABLE ALTERNATIVE



Plcoskin's scaffold is 50% safer than cadaver-sourced scaffolds, as they do not use any dangerous chemicals.

To create its scaffolds, Plcoskin uses a synthetic PCL, a biodegradable material that is commonly used to create surgical sutures. Unlike competitors' products that remain in the body for a lifetime, Plcoskin's PCL scaffolds are absorbed and replaced with the recipient's own natural tissues, minimizing the possibility of long-term side effects.



CHEAPER, WITH JUST A SINGLE SURGERY

Costs are brought down by 40% to only \$3 thousand per breast, and much less handling time is required, reducing average surgery durations from an hour and a half to only 30 minutes. Furthermore, the mesh design of the scaffolds mitigates the need for an additional reconstructive surgery.



FDA APPROVED

Plcoskin's PCL scaffolds are currently undergoing certification and clinical trials, which will take 2 years and \$5 million to complete. Once they hit the market, the company will sell the scaffolds for \$3,000 per unit. Plcoskin is adopting a B2B business model in its US expansion, selling to breast implant manufacturers who will in turn sell to hospitals.

Since its founding just three years ago, Plcoskin has attracted \$1 million in seed funding and earned FDA approval in the USA for its PCL scaffold technology.



PATENTED TECHNOLOGY

Plcoskin has also secured two patents:

- one for its Lipogenesis Mesh design;
- the other for its PCL Scaffold itself.

Though both patents are registered in Korea, the company is applying for international patent protection for its PCL Scaffold this year.

A PROJECT BASED ON EXPERIENCE

CEO and Founder Wooyeol Baek is a breast reconstruction surgeon.

After three years of practical experience in Korea, he became acutely aware of the side effects of current breast reconstruction methods. He then attended John Hopkins University Hospital as a Research Fellow, where he had the fascinating opportunity to study the development of new materials for medical use in the tissue engineering department. This experience inspired him to form Plcoskin to solve medical problems through the creation of new medical materials.

CONTACT

Wu Yeol Baek
www.plcoskin.com
wbaek@plcoskin.com
+82-10-9881-4849
50-1, Yonsei-ro, Seodaemun-gu, Seoul, Republic of Korea (ABMRC)